title: Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children.
abstract: It has been claimed that long-term prednisone treatment ameliorates the course of children with mesangiocapillary glomerulonephritis (MCGN). The International Study of Kidney Disease in Children conducted a randomized, double-blinded, placebo-controlled clinical trial in 80 children with idiopathic MCGN, including 42 patients with type I disease, 14 with type II disease, 17 with type III disease, and 7 with nontypable disease. Criteria for admission included heavy proteinuria and a glomerular filtration rate of greater than or equal to 70 ml/min per 1.73 m2. Prednisone or lactose, 40 mg/m2, was given every other day as a single morning dose. The mean duration of treatment was 41 months, renal failure being the most common reason for termination of therapy. Treatment failure was defined as an increase from baseline of 30% or more in serum creatinine, or more than 35 mumol/l. Overall, treatment failure occurred in 55% of patients treated with lactose, compared with 40% in the prednisone group. Life-table analysis showed a renal survival rate (i.e., stable renal function) at 130 months of 61% among patients receiving prednisone and 12% among patients receiving lactose (P = 0.07). Of patients with type I or III MCGN, 33% treated with prednisone were treatment failures, compared with 58% in the lactose group. Long-term treatment with prednisone appears to improve the outcome of children with MCGN.
authors.affiliation: Albert Einstein College of Medicine, Bronx, New York.
authors.forename: P
authors.initials: P
authors.lastname: Tarshish
authors.forename: J
authors.initials: J
authors.lastname: Bernstein
authors.forename: J N
authors.initials: JN
authors.lastname: Tobin
authors.forename: C M
authors.initials: CM
authors.lastname: Edelmann
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000473:pathology; D006417:Hematuria / Q000188:drug therapy; D006801:Humans; D007668:Kidney / Q000473:pathology; D007785:Lactose / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D007785:Lactose; D011241:Prednisone